Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab by Hirao, M et al.
Laboratory and febrile features after joint surgery in
patients with rheumatoid arthritis treated with
tocilizumab
M Hirao,
1 J Hashimoto,
1 H Tsuboi,
1 A Nampei,
1 H Nakahara,
2 N Yoshio,
2 T Mima,
2
H Yoshikawa,
1 N Nishimoto
2
1Department of Orthopaedics,
Osaka University Graduate
School of Medicine, Osaka,
Japan;
2Laboratory of Immune
Regulation, Graduate School of
Frontier Biosciences, Osaka
University, Osaka, Japan
Correspondence to:
J Hashimoto, Department of
Orthopaedics, Osaka University
Graduate School of Medicine,
2-2 Yamadaoka, Suita City,
Osaka 565-0871, Japan;
junha@ort.med.osaka-u.ac.jp
Accepted 9 May 2008
Published Online First
2 June 2008
This paper is freely available
online under the BMJ Journals
unlocked scheme, see http://
ard.bmj.com/info/unlocked.dtl
ABSTRACT
Objectives: To understand the acute phase responses to
surgical intervention in patients with rheumatoid arthritis
(RA) treated with the anti-interleukin (IL)6 receptor
antibody, tocilizumab.
Methods: In a retrospective 1:1 pair-matched case-
control study, 22 tocilizumab-treated RA cases and 22
cases treated with conventional disease-modifying anti-
rheumatic drugs (DMARDs) and matched for type of
surgery, age and sex were evaluated for body tempera-
ture every day, and blood C-reactive protein (CRP) levels
and white blood cell (WBC), neutrophil and lymphocyte
counts on days 21, 1, 3 and weeks 1 and 2 after joint
surgery. Safety issues were also monitored.
Results: No complications of infection or delay of wound
healing occurred in either patient group. Tocilizumab
partially, but significantly, suppressed the increase in body
temperature on postoperative days 1 and 2, compared
with DMARDs (average (SD) maximum increase in
temperature was 0.45 (0.1)uC in the tocilizumab group
and 0.78 (0.1)uC in the DMARD group; p,0.01).
Tocilizumab completely suppressed the increase in CRP
after surgery, whereas all cases treated with DMARDs
showed a significant increase of CRP at postoperative day
1 (5.5 (0.6) mg/dl; p,0.001). WBC, neutrophil and
lymphocyte counts showed no remarkable change after
surgery, and there was no significant difference in any cell
counts between the patient groups.
Conclusions: Within this small number of cases, safe
operations on patients were performed during tocilizumab
treatment. Tocilizumab suppressed fever and increase of
CRP after surgery, whereas there was no influence on the
transition in number of leukocytes. This characteristic
postoperative response should be considered during
tocilizumab treatment.
Postoperative surgical site infections represent a
serious functional and psychological disadvantage
in the course of treatment against rheumatoid
arthritis (RA), although the incidence of these
infrequent complications in joint surgery per-
formed in patients with RA is approximately
1.7% to 7.2%.
1–3 As it is necessary to detect
postoperative infections as soon as possible, body
temperature, level of C-reactive protein (CRP) and
white blood cell (WBC) count, as well as local
findings, are considered indicators of infection.
Previously published data show that the cyto-
kine interleukin (IL)6 is upregulated by surgical
trauma and involved in the febrile response.
23The
acute phase response might be diminished by
blocking the synthesis of IL6 and has been reduced
in genetically-modified animals that do not pro-
duce this mediator.
45CRP is primarily produced in
the liver in response to IL6, and CRP synthesis is
enhanced synergistically by IL1b through induc-
tion of nuclear factor (NF)kB, p50 and p65.
6–8 In
addition, IL6 positively regulates numbers of
leukocytes and neutrophils, and inhibition of the
IL6 receptor leads to a decrease in leukocytes.
91 0
In recent years, use of tocilizumab, a humanised
monoclonal antibody against IL6 receptor, has
succeeded in achieving more effective suppression
of disease activity of RA, compared to conventional
disease-modifying antirheumatic drugs
(DMARDs).
11 12 Based on the previous data, it is
unknown whether tocilizumab also suppresses
surgically-related and infection-related acute phase
responses, thereby leading to possible difficulty in
early diagnosis of postoperative infection due to
lack of observed clinical signs and symptoms in
patients treated with tocilizumab. Therefore, it is
very important to understand the details of
transition of data on blood tests and body
temperature after joint surgery in patients with
RA treated with tocilizumab. In the current study,
we examined postoperative changes in body
temperature and blood levels of CRP, WBCs,
neutrophils and lymphocytes in patients with RA
treated with tocilizumab or conventional
DMARDs.
PATIENTS AND METHODS
Patients
A total of 22 joint surgeries in our hospital were
performed on patients with RA treated with
tocilizumab. In all cases, treatment with tocilizu-
mab (8 mg/kg, every 4 weeks) was continued, and
surgery was performed between the administra-
tions of tocilizumab. The most recent infusion was
performed 16.1 (9.5) days (range 3 to 27 days)
(mean (SD)) before operation. There was no case of
postponement of infusion. All surgeries were
performed under general anaesthesia. Operations
included shoulder arthroplasty (n=1), total elbow
arthroplasty (TEA) (n=1), total hip arthroplasty
(THA) (n=1), total knee arthroplasty (TKA)
(n=9), total ankle arthroplasty (TAA) (n=3),
foot surgery (n=5) and hand surgery (n=2).
Retrospectively, we studied these 22 cases
(tocilizumab group) and compared them to 22
operations in patients with RA who received non-
biological medication (methotrexate: 6 cases; sala-
zosulfapyridine: 10 cases, bucillamine: 3 cases,
D-penicillamine: 1 case, prednisolone: 17 cases)
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patients were selected with a 1:1 pair-matched procedure,
according to age (range ¡5 years) and type and site of surgery.
Body temperature
Body temperature was measured at least three times daily (at
9.00 am, 2.00 pm and 7.00 pm) during hospitalisation. All
measurements were performed for 5 min at the external ear
canal on the same side. For analysis, we used the peak body
temperature at 1 day before surgery, during 1 and 2 days after
surgery, 1 week after surgery (week 1) and 2 weeks after
surgery (week 2). Expected fever spikes after surgery in the
tocilizumab and the DMARD groups were evaluated by change
in body temperature, as compared before the operation.
Blood samples
Venous blood samples were obtained before surgery, 1 and
3 days after surgery, 1 week after surgery and 2 weeks after
surgery. Samples were collected in EDTA tubes and analysed for
WBC counts and segmentation of WBCs (neutrophils and
lymphocytes). The change in WBCs, neutrophils and lympho-
cytes after surgery was evaluated by the percentage changes in
these parameters, compared with preoperative values. CRP
levels were measured in serum. In our hospital, the normal
reference value for CRP was ,0.2 mg/dl.
Statistical analysis
All data are expressed as mean (standard error of the mean
(SEM)). Differences between the groups were assessed by a post
hoc test using SPSS statistical analysis software (SPSS V. 15.0J;
SPSS, Chicago, Illinois, USA). A p value of ,0.05 was considered
statistically significant.
RESULTS
Postoperative complications
No complications of superficial infections, deep infections, or
delay in wound healing were observed in either group of cases.
Body temperature
As shown in table 1, there was no significant difference in
preoperative body temperature between the tocilizumab and
the DMARD groups. Both groups showed significant increases
in body temperature, as compared with that of the preoperative
day (fig 1). The expected increase in body temperature
following surgery was significantly suppressed in the tocilizu-
mab group (fig 1). Average maximum increase in body
temperature was 0.78 (0.1)uC in the DMARD group and 0.45
(0.1)uC in the tocilizumab group.
CRP
Preoperative CRP levels in the tocilizumab group were negative
in all cases except one, who showed 0.3 mg CRP/dl. All cases in
the DMARD group showed positive CRP values, and the mean
(SD) value was 3.1(0.6) mg/dl (table 1). After surgery, 18 of the
22 tocilizumab-treated cases showed no postoperative increase
in CRP, whereas the remaining 4 cases showed an increase
ranging from 0.1 to 1.0 mg/dl. In the DMARD group, all cases
showed a significant increase (day 1: 5.5 (0.6) mg/dl; 1 week
after surgery: 2.9 (0.5) mg/dl; 2 weeks after surgery: 2.2
(0.5) mg/dl).
WBC counts
As shown in table 1, there was no significant difference in
preoperative numbers of WBCs, neutrophils, or lymphocytes
between the tocilizumab and the DMARD groups. These cell
numbers showed no remarkable changes after surgery in either
group. Additionally, no significant difference between the
groups was observed in these parameters after surgery.
Therefore, cell numbers after surgery were not affected by
tocilizumab treatment.
DISCUSSION
An important issue in anti-inflammatory cytokine therapy is
the possible risk of infection, because a recent study showed
that tumour necrosis factor (TNF)a antagonists increase the
risk of infection for musculocutaneous lesions.
13 Reports on
small studies involving 12 to 16 cases of joint surgery in patients
with RA treated with TNFa antagonists, however, demon-
strated no increase in the incidence of postoperative infec-
tion.
14 15
Our hospital’s experience with 22 cases of joint surgery in
patients with RA treated with tocilizumab also showed no
postoperative surgical site infections. Although IL6 knock-out
(IL6KO) mice display significantly delayed cutaneous wound
healing compared to wild type mice,
16 17 we observed no delay in
postoperative wound healing in patients with RA treated with
tocilizumab. Because the reported incidence of postoperative
infection is around 1.7% to 7.2%,
1–3 the lack of statistical power
due to the small number of patients in our study made it
impossible to reach a conclusive result as to the influence of
tocilizumab treatment on the risk of postoperative infection.
However, our experience that there were no postoperative
infections in either tocilizumab or DMARD groups suggests the
safety of joint surgery in patients with RA during tocilizumab
treatment.
High-level production of proinflammatory cytokines includ-
ing IL6 in the inflamed synovium has a pathological role in
systemic manifestations of RA, such as fatigue, fever and
laboratory changes.
18 After surgical treatment, immune cells
such as macrophages and neutrophils or other cells such as
fibroblasts and endothelial cells are activated locally at the
surgical site by destruction of tissues, resulting in increased local
and serum levels of IL6.
21 9 Therefore, it is plausible that
inhibition of IL6 suppresses the systemic inflammatory mani-
festations of RA and surgery. Indeed, the postoperative fever
spike was partially, but significantly, suppressed by tocilizumab
treatment, as compared with DMARD treatment in the present
study.
IL6 stimulates hepatocytes to produce acute phase proteins
such as CRP, fibrinogen, a1-anti-trypsin and serum amyloid A,
and simultaneously suppresses albumin production. Previous
reports have shown that the increase in CRP and serum amyloid
A were normalised after tocilizumab treatment and the decrease
in albumin was alleviated after tocilizumab treatment.
10–12 20 In
the current study, the preoperative CRP values were normal
(,0.2) in 21 out of 22 cases in the tocilizumab group.
Furthermore, a postoperative increase in CRP was not observed
in the tocilizumab group, whereas in the DMARD group the
mean CRP level changed from a preoperative level of 3.1 mg/dl
to a maximum level of 5.5 mg/dl 1 day after surgery. This
finding clearly indicates that tocilizumab suppressed not only
an RA-related increase of CRP, but also a surgery-related
increase in CRP. Tocilizumab treatment also may suppress
infection-related symptoms after surgery. Although no infection
was observed in the patients of this study, we have experienced
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operation. As long as the infection was not severe, serum level
of CRP hardly increased while the WBC count did increase.
When the patients had severe pneumonia, they showed an
increase in CRP level and WBC count (data not shown). This
may be explained by the balance between the blood concentra-
tion of IL6 and tocilizumab, which competitively binds to IL6
receptor. Severe infection induces a high amount of IL6, which
cannot be blocked with usual doses of tocilizumab, resulting in
the increase in CRP. Similarly, if the surgical invasion is more
severe, CRP would be expected to increase even under
tocilizumab treatment. In addition, since the WBC count is
less influenced by IL6 than CRP, an increase in WBC count
could be a useful sign for possible infection. In the DMARD
group, the level of CRP was restored to the basal level within
1 week after surgery, suggesting that surgery-induced inflam-
mation resolves within 1 week in the absence of infection.
A dose-dependent reduction in the neutrophil count follow-
ing treatment with tocilizumab was reported in patients with
RA.
11 12 In the present study, preoperative absolute numbers of
WBCs and neutrophils in the tocilizumab group were smaller,
but not significantly smaller, than those in the DMARD group.
By contrast, preoperative absolute numbers of lymphocytes in
the tocilizumab group were larger, but not significantly larger,
compared to the DMARD group. No significant postoperative
changes in leukocytes, neutrophils, or lymphocytes were
observed in either group, and additionally no significant
differences between the two groups were seen at any time
after surgery. These data suggest that regulation of the increase
in leukocytes may depend on not only IL6 but also other
cytokines such as granulocyte colony stimulating factor
(G-CSF) and granulocyte-macrophage colony stimulating factor
(GM-CSF).
Our data suggest the possibility that tocilizumab might mask
the infection-induced increase in CRP and minimise the
infection-induced increase in body temperature after orthopae-
dic surgery in patients with RA. In other words, a small
postoperative increase in CRP in patients with RA may be an
important sign of the occurrence of non-arthritic types of
inflammation, such as postoperative infections. In cases of
postoperative increases in CRP in tocilizumab recipients, signs
of inflammation in other organs, such as the respiratory system,
as well as signs of infection at the surgical site, should be
checked. A WBC count may be helpful in knowing whether a
concurrent infection is occurring during tocilizumab therapy.
Furthermore, serum IL6 should be a good marker for the severity
of inflammation because tocilizumab blocks not IL6 itself but
the IL6 receptor.
45
In conclusion, although the current study evaluated only 22
cases of orthopaedic surgery in patients with RA treated with
tocilizumab and 22 cases of orthopaedic surgery in patients with
RA treated with DMARDs, no complications of superficial or
deep infection or delay in wound healing after orthopaedic
surgery were observed. Additionally, we demonstrated that the
increase in CRP was completely suppressed and the rise in body
Figure 1 Changes in body temperature, C-reactive protein (CRP) levels and numbers of white blood cells (WBCs; neutrophils and lymphocytes) after
surgery. Values are mean (SD). *Significant difference, as compared to values before surgery. NS, no significant difference between the two groups.
Dotted lines: disease-modifying antirheumatic drug (DMARD) group. Unbroken lines: tocilizumab group. A. Graph shows the change in body
temperature, as compared before surgery. p: p Value for the difference between the DMARD group and the tocilizumab group. B. Graph shows the
absolute value of CRP level. p: p Value for the difference between the two groups. C. Graph shows the percentage change in total number of WBCs. D.
Graph shows the percentage change in numbers of neutrophils. E. Graph shows the percentage change in numbers of lymphocytes.
Table 1 Characteristics of the cases before surgery
Parameter
No. treated with
DMARDs
No. treated with
tocilizumab p Value
Body temperature (uC) 36.5 (0.3) 36.6 (0.2) NS
CRP (mg/dl) 3.1 (0.6) 0.02 (0.02) ,0.001
WBCs/dl 8144 (3229) 7267 (2757) NS
Neutrophils/ml 6716 (2973) 5424 (2545) NS
Lymphocytes/ml 978 (413) 1384 (706) NS
DAS28 (CRP) score 4.4 (0.9) 2.7 (0.7) ,0.001
Prednisolone (mg/day) 7.0 (5.1) 6.5 (5.1) NS
Values are mean (SD). p Value is for the difference between the DMARD group and the
tocilizumab group.
CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; DMARD, disease-
modifying antirheumatic drug; NS, not significant; WBC, white blood cell.
Extended report
656 Ann Rheum Dis 2009;68:654–657. doi:10.1136/ard.2008.090068temperature was partially suppressed after joint surgery in
tocilizumab-treated patients with RA, whereas tocilizumab had
no significant influence on the number of leukocytes.
Considering these characteristic postoperative responses in
patients with RA treated with tocilizumab, we should carefully
perform orthopaedic surgery on the patients.
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